Inovio Pharma Stock
Inovio Pharma Stock
Our community identified positive and negative aspects for Inovio Pharma stock for the coming years. 1 users see the criterium "Business model" as a plus for the Inovio Pharma stock. On the other hand our users think that "Worthwhile Investment for the next years" could be a problem in the future.
Pros and Cons of Inovio Pharma in the next few years
Pros
?
M***** P*******
?
B****
?
S********** s********
Cons
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Inovio Pharma vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Inovio Pharma | - | - | - | - | - | - | - |
| Evolus Inc | -0.040% | -0.496% | -14.130% | -33.154% | -4.330% | -42.703% | -41.085% |
| Heron Therapeutics Inc. | -1.990% | 2.964% | 15.558% | -71.508% | -61.329% | -69.229% | -95.846% |
| Rhythm Pharmaceuticals | -1.080% | 1.667% | -5.181% | 26.207% | -2.139% | 479.114% | 535.417% |
Comments
Inovio Pharmaceuticals (INO) was downgraded by Wall Street Zen from "hold" to "sell".
Show more
Ratings data for INO provided by MarketBeat
Inovio Pharmaceuticals (NASDAQ:INO) had its "overweight" rating reaffirmed by analysts at UBS Group AG.
Show more
Ratings data for INO provided by MarketBeat
Inovio Pharmaceuticals (NASDAQ:INO) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
Show more
Ratings data for INO provided by MarketBeat